

# Martin BortlÄ-k

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5635224/publications.pdf>

Version: 2024-02-01

78  
papers

2,532  
citations

218677

26  
h-index

189892

50  
g-index

78  
all docs

78  
docs citations

78  
times ranked

3574  
citing authors

#	ARTICLE	IF	CITATIONS
1	Genetic factors conferring an increased susceptibility to develop Crohn's disease also influence disease phenotype: results from the IBDchip European Project. <i>Gut</i> , 2013, 62, 1556-1565.	12.1	221
2	Infliximab trough levels may predict sustained response to infliximab in patients with Crohn's disease. <i>Journal of Crohn's and Colitis</i> , 2013, 7, 736-743.	1.3	211
3	Natural disease course of Crohn's disease during the first 5 years after diagnosis in a European population-based inception cohort: an Epi-IBD study. <i>Gut</i> , 2019, 68, 423-433.	12.1	176
4	Nonadherence in inflammatory bowel disease: Results of factor analysis. <i>Inflammatory Bowel Diseases</i> , 2007, 13, 1244-1249.	1.9	133
5	DNA repair genetic polymorphisms and risk of colorectal cancer in the Czech Republic. <i>Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis</i> , 2008, 638, 146-153.	1.0	103
6	Natural Disease Course of Ulcerative Colitis During the First Five Years of Follow-up in a European Population-based Inception Cohort—An Epi-IBD Study. <i>Journal of Crohn's and Colitis</i> , 2019, 13, 198-208.	1.3	100
7	Exogenous alkaline phosphatase for the treatment of patients with moderate to severe ulcerative colitis. <i>Inflammatory Bowel Diseases</i> , 2010, 16, 1180-1186.	1.9	86
8	Incidence and initial disease course of inflammatory bowel diseases in 2011 in Europe and Australia: Results of the 2011 ECCO-EpiCom inception cohort. <i>Journal of Crohn's and Colitis</i> , 2014, 8, 1506-1515.	1.3	82
9	Environmental factors in a population-based inception cohort of inflammatory bowel disease patients in Europe—An ECCO-EpiCom study. <i>Journal of Crohn's and Colitis</i> , 2014, 8, 607-616.	1.3	81
10	Impact of Anti-Tumor Necrosis Factor Alpha Antibodies Administered to Pregnant Women With Inflammatory Bowel Disease on Long-term Outcome of Exposed Children. <i>Inflammatory Bowel Diseases</i> , 2014, 20, 495-501.	1.9	79
11	Practical guidelines on endoscopic treatment for Crohn's disease strictures: a consensus statement from the Global Interventional Inflammatory Bowel Disease Group. <i>The Lancet Gastroenterology and Hepatology</i> , 2020, 5, 393-405.	8.1	78
12	Health-care costs of inflammatory bowel disease in a pan-European, community-based, inception cohort during 5 years of follow-up: a population-based study. <i>The Lancet Gastroenterology and Hepatology</i> , 2020, 5, 454-464.	8.1	76
13	Efficacy of Infliximab Biosimilar CT-P13 Induction Therapy on Mucosal Healing in Ulcerative Colitis. <i>Journal of Crohn's and Colitis</i> , 2016, 10, 1273-1278.	1.3	72
14	Biological therapy in inflammatory bowel diseases: Access in Central and Eastern Europe. <i>World Journal of Gastroenterology</i> , 2015, 21, 1728.	3.3	64
15	Pregnancy and newborn outcome of mothers with inflammatory bowel diseases exposed to anti-TNF- $\alpha$ therapy during pregnancy: three-center study. <i>Scandinavian Journal of Gastroenterology</i> , 2013, 48, 951-958.	1.5	63
16	Role of interventional inflammatory bowel disease in the era of biologic therapy: a position statement from the Global Interventional IBD Group. <i>Gastrointestinal Endoscopy</i> , 2019, 89, 215-237.	1.0	61
17	Health-related quality of life improves during one year of medical and surgical treatment in a European population-based inception cohort of patients with Inflammatory Bowel Disease—An ECCO-EpiCom study. <i>Journal of Crohn's and Colitis</i> , 2014, 8, 1030-1042.	1.3	59
18	Safety of Anti-TNF-Alpha Therapy During Pregnancy on Long-term Outcome of Exposed Children: A Controlled, Multicenter Observation. <i>Inflammatory Bowel Diseases</i> , 2019, 25, 789-796.	1.9	53

#	ARTICLE	IF	CITATIONS
19	Discontinuation of anti-tumor necrosis factor therapy in inflammatory bowel disease patients: a prospective observation. <i>Scandinavian Journal of Gastroenterology</i> , 2016, 51, 196-202.	1.5	51
20	Costs and Resource Utilization for Diagnosis and Treatment During the Initial Year in a European Inflammatory Bowel Disease Inception Cohort. <i>Inflammatory Bowel Diseases</i> , 2015, 21, 121-131.	1.9	47
21	Systematic versus Endoscopy-driven Treatment with Azathioprine to Prevent Postoperative Ileal Crohn's Disease Recurrence. <i>Journal of Crohn's and Colitis</i> , 2015, 9, 617-624.	1.3	44
22	Pentane and other volatile organic compounds, including carboxylic acids, in the exhaled breath of patients with Crohn's disease and ulcerative colitis. <i>Journal of Breath Research</i> , 2018, 12, 016002.	3.0	43
23	Infliximab Biosimilar (Remsima,®) in Therapy of Inflammatory Bowel Diseases Patients: Experience from One Tertiary Inflammatory Bowel Diseases Centre. <i>Digestive Diseases</i> , 2017, 35, 91-100.	1.9	42
24	Treatment Steps, Surgery, and Hospitalization Rates During the First Year of Follow-up in Patients with Inflammatory Bowel Diseases from the 2011 ECCO-Epicom Inception Cohort. <i>Journal of Crohn's and Colitis</i> , 2015, 9, 747-753.	1.3	38
25	Serum trough infliximab levels: A comparison of three different immunoassays for the monitoring of CT-P13 (infliximab) treatment in patients with inflammatory bowel disease. <i>Biologicals</i> , 2016, 44, 33-36.	1.4	32
26	Impaired Deoxyribonuclease I Activity in Patients with Inflammatory Bowel Diseases. <i>Autoimmune Diseases</i> , 2011, 2011, 1-5.	0.6	31
27	Vitamin D deficiency in a European inflammatory bowel disease inception cohort: an Epi-IBD study. <i>European Journal of Gastroenterology and Hepatology</i> , 2018, 30, 1297-1303.	1.6	27
28	Frequency and characteristics of infusion reactions during biosimilar infliximab treatment in inflammatory bowel diseases: results from Central European nationwide cohort. <i>Expert Opinion on Drug Safety</i> , 2017, 16, 885-890.	2.4	26
29	What is the origin of ulcerative colitis? Still more questions than answers. <i>Postgraduate Medical Journal</i> , 2006, 82, 620-625.	1.8	23
30	Occurrence of Anaemia in the First Year of Inflammatory Bowel Disease in a European Population-based Inception Cohort: An ECCO-EpiCom Study. <i>Journal of Crohn's and Colitis</i> , 2017, 11, 1213-1222.	1.3	23
31	Variants of <i>CARD15</i> , <i>TNFA</i> and <i>PTPN22</i> and susceptibility to Crohn's disease in the Czech population: high frequency of the <i>CARD15</i> 1007fs. <i>Tissue Antigens</i> , 2008, 71, 538-547.	1.0	22
32	Health care and patients' education in a European inflammatory bowel disease inception cohort: An ECCO-EpiCom study. <i>Journal of Crohn's and Colitis</i> , 2014, 8, 811-818.	1.3	21
33	Non-adherence to treatment in inflammatory bowel disease in Czech Republic. <i>Journal of Crohn's and Colitis</i> , 2007, 1, 77-81.	1.3	20
34	Anticarbhydrate antibodies as markers of inflammatory bowel disease in a Central European cohort. <i>European Journal of Gastroenterology and Hepatology</i> , 2010, 22, 144-150.	1.6	19
35	Disease course of inflammatory bowel disease unclassified in a European population-based inception cohort: An Epi-IBD study. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2019, 34, 996-1003.	2.8	19
36	Differences in the placental pharmacokinetics of vedolizumab and ustekinumab during pregnancy in women with inflammatory bowel disease: a prospective multicentre study. <i>Therapeutic Advances in Gastroenterology</i> , 2021, 14, 175628482110327.	3.2	19

#	ARTICLE	IF	CITATIONS
37	Fatal Myelotoxicity After Azathioprine Treatment. <i>Nucleosides, Nucleotides and Nucleic Acids</i> , 2008, 27, 661-665.	1.1	18
38	The use of 5-aminosalicylate for patients with Crohn's disease in a prospective European inception cohort with 5 years follow-up: an Epi-IBD study. <i>United European Gastroenterology Journal</i> , 2020, 8, 949-960.	3.8	17
39	NKX2-3 and IRGM variants are associated with disease susceptibility to IBD in Eastern European patients. <i>World Journal of Gastroenterology</i> , 2010, 16, 5233.	3.3	17
40	Improved HPLC Analysis of Serum 7 $\alpha$ -Hydroxycholest-4-en-3-one, a Marker of Bile Acid Malabsorption. <i>Clinical Chemistry</i> , 2008, 54, 1087-1088.	3.2	16
41	Safety of Ustekinumab and Vedolizumab During Pregnancy—Pregnancy, Neonatal, and Infant Outcome: A Prospective Multicentre Study. <i>Journal of Crohn's and Colitis</i> , 2022, 16, 1808-1815.	1.3	16
42	Anti-inflammatory effect of biological treatment in patients with inflammatory bowel diseases: Calprotectin and IL-6 changes do not correspond to sRAGE changes. <i>Scandinavian Journal of Clinical and Laboratory Investigation</i> , 2010, 70, 294-299.	1.2	14
43	Infliximab dependency is related to decreased surgical rates in adult Crohn's disease patients. <i>European Journal of Gastroenterology and Hepatology</i> , 2010, 22, 1196-1203.	1.6	12
44	Mutation analysis of the MYH gene in unrelated Czech APC mutation-negative polyposis patients. <i>European Journal of Cancer</i> , 2007, 43, 1617-1621.	2.8	11
45	Visceral leishmaniasis with cutaneous symptoms in a patient treated with infliximab followed by fatal consequences. <i>Dermatologic Therapy</i> , 2014, 27, 131-134.	1.7	10
46	Novel porcine model of Crohn's disease anastomotic stricture suitable for evaluation and training of advanced endoscopic techniques. <i>Gastrointestinal Endoscopy</i> , 2021, 93, 250-256.	1.0	8
47	Polymorphisms of the TPMT Gene in the Czech Healthy Population and Patients with Inflammatory Bowel Disease. <i>Nucleosides, Nucleotides and Nucleic Acids</i> , 2008, 27, 835-838.	1.1	7
48	Sa1957 Switching of Patients With Inflammatory Bowel Disease From Original Infliximab (Remicade®) to Biosimilar Infliximab (Remsima®, Ć) Is Effective and Safe. <i>Gastroenterology</i> , 2016, 150, S416.	1.3	7
49	Infliximab biosimilar CT-P13 therapy is effective in maintaining endoscopic remission in ulcerative colitis—results from multicenter observational cohort. <i>Expert Opinion on Biological Therapy</i> , 2018, 18, 1181-1187.	3.1	7
50	Guidelines for the administration of biological therapy in patients with Crohn's disease and ulcerative colitis: third updated edition. <i>Gastroenterologie A Hepatologie</i> , 2016, 70, 11-26.	0.1	7
51	Endoscopic Balloon Dilatation of Anastomotic Strictures in Patients With Crohn's Disease: Effect of Immediate Endoscopic Success and Biological Therapy. <i>Gastroenterology</i> , 2011, 140, S-281.	1.3	2
52	Phosphatidylserine-dependent anti-prothrombin antibodies (aPS/PT) in infliximab-treated patients with inflammatory bowel diseases. <i>Autoimmunity Highlights</i> , 2013, 4, 27-32.	3.9	2
53	515 Biosimilar Infliximab Is Effective and Safe in Inflammatory Bowel Disease Patients Na <sup>+</sup> ve to Anti-TNF Therapy: A Tertiary Center Experience. <i>Gastroenterology</i> , 2016, 150, S106.	1.3	2
54	A novel postgraduate endoscopic course using a large animal model of secondary Crohn's disease stricture. <i>Surgical Endoscopy and Other Interventional Techniques</i> , 2021, 35, 3199-3204.	2.4	2

#	ARTICLE	IF	CITATIONS
55	Biosimilar infliximab in anti-TNF-naïve IBD patients – 1-year clinical follow-up. <i>Gastroenterologie A Hepatologie</i> , 2016, 70, 514-522.	0.1	2
56	Deficiency of Adenomatous Polyposis Coli protein in sporadic colorectal adenomas and its associations with clinical phenotype and histology. <i>World Journal of Gastroenterology</i> , 2006, 12, 3901.	3.3	2
57	Vedolizumab – a novel anti-integrin antibody with high gastrointestinal selectivity. <i>Gastroenterologie A Hepatologie</i> , 2014, 68, 481-484.	0.1	2
58	Sa1958 No Difference in Immunogenicity of the Original and Biosimilar Infliximab in Patients With Inflammatory Bowel Disease: Short-Term Results. <i>Gastroenterology</i> , 2016, 150, S416.	1.3	1
59	Recommendation of surgical treatment in patients with inflammatory bowel diseases – part 2: Crohn's disease. <i>Gastroenterologie A Hepatologie</i> , 2015, 69, 223-238.	0.1	1
60	Long-term functional outcomes and quality of life after restorative proctocolectomy and ileal pouch-anal anastomosis. <i>Gastroenterologie A Hepatologie</i> , 2016, 70, 38-44.	0.1	1
61	Budesonide MMX (Cortiment® 9 mg) in the treatment of ulcerative colitis in real clinical practice. <i>Gastroenterologie A Hepatologie</i> , 2016, 70, 509-513.	0.1	1
62	Czech Society of Gastroenterology guidelines for diagnostic and therapeutic colonoscopy. <i>Gastroenterologie A Hepatologie</i> , 2016, 70, 523-538.	0.1	1
63	Conventional and biological therapy for inflammatory bowel disease. <i>Vnitřní Lekarství</i> , 2018, 64, 642-653.	0.2	1
64	Endoscopic Mucosal Resection of the Large and Sessile Colorectal Neoplasms. A Prospective Assessment of the Efficacy and Safety. <i>Gastrointestinal Endoscopy</i> , 2004, 59, P281.	1.0	0
65	Endoscopic Diagnosis and Treatment of Late Complications of Gastric Bandage. <i>Gastrointestinal Endoscopy</i> , 2006, 63, AB184.	1.0	0
66	S1492: Endoscopic Treatment of Zenker's Diverticulum: Comparison of Two Techniques. <i>Gastrointestinal Endoscopy</i> , 2010, 71, AB176.	1.0	0
67	Outcomes of Treatment With Infliximab for Ulcerative Colitis and Predictors of Sustained Clinical Response. <i>Gastroenterology</i> , 2011, 140, S-591-S-592.	1.3	0
68	Efficacy of Intensification Regimes of Biologic Therapy in Patients With Inflammatory Bowel Disease and Secondary Non-Response: Experience of a Single Referral Centre. <i>Gastroenterology</i> , 2011, 140, S-591.	1.3	0
69	Relationship Between Serum Trough Infliximab Levels and Serum Albumin in Patients With Inflammatory Bowel Diseases. <i>Gastroenterology</i> , 2011, 140, S-282.	1.3	0
70	Predictors of Sustained Response to Infliximab in Patients With Crohn's Disease: A Single Cohort Study. <i>Gastroenterology</i> , 2011, 140, S-593.	1.3	0
71	Biosimilar Infliximab in Anti-TNF Naïve IBD Patients and One-Year Clinical Follow-Up. <i>Gastroenterology</i> , 2017, 152, S398-S399.	1.3	0
72	Combination of endoscopic treatment – septectomy and stricturotomy in the afferent ileal limb of the ileal pouch. <i>Endoscopy</i> , 2018, 50, 820-821.	1.8	0

#	ARTICLE	IF	CITATIONS
73	Sodium hyaluronate: a new option in the treatment of ulcerative colitis? Information about new product. <i>Gastroenterologie A Hepatologie</i> , 2014, 68, 468-469.	0.1	0
74	New approaches in the follow-up of patients suffering from inflammatory bowel diseases. <i>Gastroenterologie A Hepatologie</i> , 2015, 69, .	0.1	0
75	Recommendation of surgical treatment in patients with inflammatory bowel diseases " part 3: ulcerative colitis, indications for surgery. <i>Gastroenterologie A Hepatologie</i> , 2016, 70, 252-261.	0.1	0
76	Rifaximin. <i>Gastroenterologie A Hepatologie</i> , 2017, 71, 271-272.	0.1	0
77	Recommendations of the Working Group for IBD for the Diagnosis and Drug Treatment of Ulcerative Colitis. <i>Gastroenterologie A Hepatologie</i> , 2022, 76, 13-28.	0.1	0
78	Safety of vedolizumab and ustekinumab in the treatment of pregnant women with inflammatory bowel disease " a multicentre retrospective-prospective observational study. <i>Gastroenterologie A Hepatologie</i> , 2022, 76, 46-54.	0.1	0